Global CAR T Cell Therapy Market Research 2022: Opportunity & Clinical Pipeline Insights to 2028 – Insight On More Than 600 CAR T Cell Therapies…

Dublin, June 16, 2022 (GLOBE NEWSWIRE) -- The "Global CAR T Cell Therapy Market Opportunity & Clinical Pipeline Insight 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.

Global CAR T cell therapy market opportunity is expected to surpass US$ 15 Billion by 2028

The development of CAR T cell therapy will gather momentum from the increasing number of investors, designers, and analysts in the guide therapy.

Rising frequencies of cancer across the globe together with the relentless technological advancement for dependable and effective cancer treatment is expected to support the growth of the worldwide CAR-T cell therapy market. Furthermore, heavy investments in clinical research and development in cell therapy are estimated to boost the market for CAR-T cell therapy in the years to come.

The report provides information on the globally approved CAR T cell therapies along with their price, dosage, and sales analysis. The report analyzes and forecasts the size of the global CAR-T cell therapy market.

The report delivers a full-scale exploration of market dynamics and factors that are manipulating the growth of the global CAR-T cell therapy market. The report also gives a competitive analysis of major market players that will give a competitive advantage to customers in their respective businesses.

Chimeric antigen receptor (CAR) T cell therapy is a novel immunotherapeutic approach that is indicated for the management of cancer. CAR T-cell therapy is a type of therapy in which the T-cells are taken from the blood of the patient, which is then modified in a lab by the addition of a gene for a man-made receptor (chimeric antigen receptor).

This aids in better recognizing of specific cancer cell antigens. The CAR T-cells are then given back to the patient. To date, 6 CAR T-cell therapy products including Kymriah (tisagenlecleucel), yescarta (axicabtagene), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), and Abecma (idecabtagene vicleucel) have been approved by FDA for the management of wide range of cancers. In addition to this, Relmacabtagene autoleucel have been approved in China.

The introduction of CAR T cell therapies has shown high adoption rates in a short span of time has propelled further research and development activities in this domain. Apart from hematological malignancies, the researchers are also expanding the role of CAR T cell therapies in solid tumors which will propel the growth of the market.

For instance, a recent research study demonstrated that infusing immune cells into patients has shown early promise by shrinking tumors in digestive system. The interim results demonstrated that tumors in nearly 50% of the 37 patients so far reduced in size after the therapy.

The global CAR T cell therapy market is highly consolidated with several key players. The pharmaceutical giants in the market are increasingly partnering or collaborating with technology companies to integrate advanced technologies for the betterment of CAR-T therapy or to expand their geographical presence.

For instance, Bayer and Atara Biotherapeutics entered into a worldwide license agreement for the development of next-generation ATA3271 which is mesothelin-directed CAR-T cell therapy. The agreement also aims to develop ATA2271, for the management of high mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small-cell lung cancer.

Among drug types, Yescarta is currently dominating the market. Yescarta (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma.

Recently in 2022, regulatory bodies expanded the approval of drugs for the management of large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within a year of first-line chemotherapy. The wide range of therapeutic indications as well as the global availability of the drug is the major factors which are the major factors aiding in the dominance of these factors.

Report Highlights:

Key Topics Covered:

1. Research Methodology

2. Chimeric Antigen Receptor (CAR) T Cell Therapy - Next Era in Immuno Oncology

3. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design3.1 Structure of CAR-T Cell3.2 1st Generation Chimeric Antigen Receptor3.3 2nd & 3rd Generation CAR-T Cell3.4 Principle of Chimeric Antigen Receptor Design

4. Approaches to Improve the Efficiency of CAR-T Cell Therapy

5. CAR T Cell Therapy Manufacturing Cost Analysis

6. Emerging In-Vivo Induced CAR T Cell Therapies6.1 Need of In-Vivo CAR T Cell Therapy6.2 In-Vivo CAR T Cell Platform; VivoVec, TumorTag, & RACR/CAR6.3 Key Drug in Research & Development

7. Global CAR T Cell Therapy Market Outlook 2022 - 20287.1 Market Overview7.2 Future Market Opportunity

8. Globally Approved CAR T Cell Therapies - Pricing, Dosage & Sales Analysis 20288.1 Tisagenlecleucel (Kymriah)8.2 Axicabtagene Ciloleuce (Yescarta)8.3 Brexucabtagene Autoleucel (Tecartus)8.4 Lisocabtagene maraleucel (Breyanzi)8.5 Idecabtagene Vicleucel (Abecma)8.6 Relmacabtagene autoleucel (Carteyva)8.7 Ciltacabtagene autoleucel (Carvykti)

9. US CAR T Cell Therapy Market Outlook9.1 Approved & Key CAR T Cell Therapy Products in US9.2 Market Overview9.3 Current Reimbursement Scenario

10. Europe CAR T Cell Therapy Market Outlook10.1 Approved & Key CAR T Cell Therapy Products in Europe10.2 UK10.3 Germany10.4 Spain10.5 France10.6 Rest of Europe10.7 Current Reimbursement Scenario

11. China CAR T Cell Therapy Market Outlook11.1 Approved & Key CAR T Cell Therapy Products in China11.2 Current Market Size & Forecast

12. Japan CAR T Cell Therapy Market Outlook12.1 Approved & Key CAR T Cell Therapy Products in Japan12.2 Market Overview12.3 Current Reimbursement Scenario

13. South Korea CAR T Cell Therapy Market Outlook13.1 Approved & Key CAR T Cell Therapies in South Korea13.2 Future Market Opportunity

14. Australia CAR T Cell Therapy Market Outlook14.1 Approved & Key CAR T Cell Products in Australia14.2 Australia CAR T Cell Therapy Market14.3 Current Reimbursement Scenario

15. Taiwan CAR T Cell Therapy Market Outlook

16. Global CAR T Cells Clinical Pipeline Overview16.1 By Company16.2 By County16.3 By Indication16.4 By Phase

17. Global CAR T Cells Clinical Pipeline By Company, Indication & Phase17.1 Research17.2 Preclinical17.3 Clinical17.4 Phase-I17.5 Phase-I/II17.6 Phase-II17.7 Phase-III17.8 Registered

18. Marketed CAR T Cell Therapy Clinical insight18.1 Breyanzi18.2 CARVYKTI18.3 Yescarta18.4 Kymriah18.5 Abecma18.6 Tecartus

19. Global CAR-T Cell Therapy Market Dynamics19.1 Favorable Parameters19.2 Market Challenges

20. Competitive Landscape20.1 Autolus20.2 Bellicum20.3 Bluebird20.4 Celgene20.5 Cellectis20.6 Celyad20.7 Eureka Therapeutics20.8 Fortress Biotech20.9 Immune Therapeutics20.10 Juno Therapeutics20.11 Kite Pharma20.12 Novartis20.13 Sorrento therapeutics20.14 TILT Biotherapeutics20.15 Ziopharm

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/4xxf5g

Go here to read the rest:
Global CAR T Cell Therapy Market Research 2022: Opportunity & Clinical Pipeline Insights to 2028 - Insight On More Than 600 CAR T Cell Therapies...